Search

Your search keyword '"Kawata, Kazuhito"' showing total 388 results

Search Constraints

Start Over You searched for: Author "Kawata, Kazuhito" Remove constraint Author: "Kawata, Kazuhito"
388 results on '"Kawata, Kazuhito"'

Search Results

51. A Case of Adrenocortical Carcinoma With a Favorable Tumor Control by Radiofrequency Ablation for Liver Metastasis.

53. Phosphatidylcholine in bile‐derived small extracellular vesicles as a novel biomarker of cholangiocarcinoma

54. Hepatic Angiosarcoma with Peliosis Hepatis

55. Association of PPI and antibiotics with the clinical outcomes of HCC patients receiving atezolizumab and bevacizumab: A multicenter analysis

56. Gallbladder perforation following peroral cholangioscopy‐guided lithotripsy: A case report

57. Rifaximin Improves Liver Functional Reserve by Regulating Systemic Inflammation

58. Identification of clinical phenotypes associated with poor prognosis in patients with nonalcoholic fatty liver disease via unsupervised machine learning.

59. A multicenter, retrospective, cohort study shows platelet counts predict HCC development in patients with NAFLD

60. Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab

61. Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab

62. Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study

63. Risk factors for portopulmonary hypertension in patients with cirrhosis: a prospective, multicenter study

64. Nutritional status is associated with prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab

65. Association of serum albumin levels and long-term prognosis in patients with biopsy- confirmed nonalcoholic fatty liver disease

66. Arg-Gly-Asp-binding integrins activate hepatic stellate cells via the hippo signaling pathway

67. DILATED MAIN PANCREATIC DUCT CAN BE A NEGATIVE PREDICTOR OF PANCREATITIS RELATED TO BILIARY SEMS INSERTION ACROSS THE PAPILLA

68. Validation of the utility of Agile scores to identify advanced fibrosis and cirrhosis in Japanese patients with nonalcoholic fatty liver disease.

69. Noninvasive tests predict liver‐related events and mortality in patients with nonalcoholic fatty liver disease: sub‐analysis of the CLIONE‐Asia study.

70. Development and validation of a modified albumin-bilirubin grade and α-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumab.

71. SAT-101 Morphological changes in esophageal varices in patients with HCVrelated cirrhosis who achieved sustained virological response by direct-acting antivirals

72. DILATED MAIN PANCREATIC DUCT CAN BE A NEGATIVE PREDICTOR OF PANCREATITIS RELATED TO BILIARY SEMS INSERTION ACROSS THE PAPILLA

74. Association of Serum Albumin Levels and Long-Term Prognosis in Patients with Biopsy-Confirmed Nonalcoholic Fatty Liver Disease.

75. Multicenter, retrospective, cohort study shows platelet counts predict hepatocellular carcinoma development in patients with nonalcoholic fatty liver disease.

76. Diagnostic accuracy of enhanced liver fibrosis test for nonalcoholic steatohepatitis‐related fibrosis: Multicenter study.

77. Mac‐2‐binding protein glycan isomer predicts all malignancies after sustained virological response in chronic hepatitis C

78. Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: A multicenter retrospective study

79. Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581]

80. Environmental factors, medical and family history, and comorbidities associated with primary biliary cholangitis in Japan: a multicenter case–control study

81. C-Reactive Protein to Albumin Ratio Predicts Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Analysis

83. An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs

85. Azathioprine‐induced severe myelosuppression accompanied by massive hair loss and painful oral ulcer in an autoimmune hepatitis patient with NUDT15 minor variant: A case report

86. Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib

87. Impact of Modified Albumin–Bilirubin Grade on Survival in Patients With HCC Who Received Lenvatinib: An Analysis Using Time-Dependent ROC

89. Relationship of Atezolizumab plus Bevacizumab Treatment with Muscle Volume Loss in Unresectable Hepatocellular Carcinoma Patients: Multicenter Analysis

90. Glasgow prognostic score predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib: a multicenter analysis.

91. Efficacy of Lenvatinib for Unresectable Hepatocellular Carcinoma Based on Background Liver Disease Etiology: Multi-center Retrospective Study

92. SAT-448 - Serum levels of type IV collagen 7S can predict liver-related mortality and events as well as advanced fibrosis: a multi-center study

93. THU-131 - Incidence and risk factors of esophagogastric varices bleeding in patients with advanced hepatocellular carcinoma treated with lenvatinib

94. WED-293 - Prognostic value of serum ALP levels during additional treatment in Japanese patients with primary biliary cholangitis treated with ursodeoxycholic acid and bezafibrate

95. Common Drug Pipelines for the Treatment of Diabetic Nephropathy and Hepatopathy: Can We Kill Two Birds with One Stone?

96. Lenvatinib versus sorafenib in first‐line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis

98. The ursodeoxycholic acid response score predicts pathological features in primary biliary cholangitis

Catalog

Books, media, physical & digital resources